Jan 8 (Reuters) - The U.S. Food and Drug Administration said on Wednesday it approved Merck & Co Inc’s Keytruda for the treatment of a type of bladder cancer.
The therapy was approved for patients with a high-risk non-muscle invasive bladder cancer who are ineligible for or have opted out of surgical removal of part of the bladder. (Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Aditya Soni)
Our Standards: The Thomson Reuters Trust Principles.